2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Abstract Number: 077

Integrated Spatial Transcriptomics and Proteomics in Reveals Aberrant Lymphoid Networks in Pediatric Lupus Nephritis
Abstract Number: 078

Development of A High-Parameter Whole Blood Thrombo-inflammation Flow Cytometry Panel for Research in Pediatric Autoimmune Diseases
Abstract Number: 079

Still’s Disease Associated Lung Disease: Update From the European Registry
Abstract Number: 080

Expansion of Type I IFN-driven ISGhigh Monocytes and Identification of MAS-Associated CD8+ T cell Population During Macrophage Activation Syndrome
Abstract Number: 081

Therapeutic Drug Monitoring in Pediatric Rheumatology: A Survey of Providers in North America
Abstract Number: 082

Ophthalmic Predictors of Response to Methotrexate Monotherapy in Pediatric Non-Infectious Uveitis
Abstract Number: 083

Relative Risk of a Thrombotic Event in Janus Kinase Inhibitor Use for JIA using the Epic Cosmos Database
Abstract Number: 084

Early Life Exposures and Risk of Spondyloarthritis: A Population-Based Case-Control Study
Abstract Number: 085

Outcomes of Oligoarticular Juvenile Idiopathic Arthritis Patients Treated with Intra-articular Glucocorticoids: Can We Predict Successful Treatment?
Abstract Number: 086

APOL1 Focal Segmental Glomerulosclerosis Requiring Renal Transplant, the Burden of Childhood onset Autoimmune and Autoinflammatory Disease
Abstract Number: 087

A Growing Problem: Factors Associated with Growth Disturbances in Juvenile Localized Scleroderma
Abstract Number: 088

Demographics and Clinical Features of Deficiency of adenosine deaminase 2: A Large Quaternary Single Center Experience
Abstract Number: 089

Anti-CD19 CAR-T Cell Therapy for the Treatment of Severe/Refractory Pediatric Autoimmune Diseases: A Single-Center Case Series
Abstract Number: 090

Characterizing CNS MRI Abnormalities in Pediatric ANCA-Associated Vasculitis
Abstract Number: 091

Psychosocial Burden in Juvenile Systemic Sclerosis: Insights from PedQL Outcomes

« Previous Page
1
…
4
5
6
7
8
…
10
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].